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The Peruvian National Tuberculosis Control Program 
issued guidelines in 2006 specifying criteria for culture and 
drug-susceptibility testing (DST), including district-level rapid 
DST. All patients referred for culture and DST in 2 districts 
of Lima, Peru, during January 2005–November 2008 were 
monitored prospectively. Of 1,846 patients, 1,241 (67.2%) 
had complete DST results for isoniazid and rifampin; 419 
(33.8%) patients had multidrug-resistant (MDR) TB at the 
time of referral. Among patients with new smear-positive 
TB, household contact and suspected category I failure 
were associated with MDR TB, compared with concurrent 
regional surveillance data. Among previously treated 
patients with smear-positive TB, adult household contact, 
suspected category II failure, early relapse after category I, 
and multiple previous TB treatments were associated with 
MDR TB, compared with concurrent regional surveillance 
data. The proportion of MDR TB detected by using guidelines 
was higher than that detected by a concurrent national drug-
resistance survey, indicating that the strategy effectively 
identiﬁ  ed patients for DST.
M
ultidrug-resistant tuberculosis (MDR TB) is deﬁ  ned 
as infection with Mycobacterium tuberculosis with 
in vitro resistance to at least isoniazid and rifampin. The 
incidence of MDR TB disease was estimated to be 0.5 
million in 2007, with a prevalence of as many as 2 million 
cases worldwide (1). Although no single best approach 
to MDR TB treatment has been recognized, rapid drug-
susceptibility testing (DST) and prompt initiation of 
effective treatment are achievable goals. Ideally, treatment 
is based on timely, accurate DST, but if universal DST is 
not possible or not yet available, the national TB control 
program can prioritize patients at increased risk for MDR 
TB.
Rapid DST methods should minimize delays to 
initiation of appropriate treatment (2,3). Numerous assays 
have been developed that have characteristics suitable for 
use in low-income settings, including low cost, modest 
technical demand, and high accuracy (4–6). The nitrate 
reductase assay (NRA), also known as the Griess method, 
has demonstrated acceptable sensitivity, speciﬁ  city, 
and speed compared with conventional DST and rapid 
phenotypic DST methods (7,8). This phenotypic assay was 
developed in Russia as a low-cost drug-susceptibility test 
that can be used in areas of moderate technical capacity 
(9). The method is based on a nitrate-reductase colorimetric 
reaction that uses Lowenstein-Jensen (LJ) medium 
prepared with antimicrobial drugs (9). Although initially 
validated as an indirect method, it was implemented as a 
direct method by the Peruvian National Institute of Health 
(INS) (10). The NRA yields drug-susceptibility information 
to isoniazid and rifampin 21–28 days after inoculating a 
smear-positive sputum sample (direct method) or 8–10 
days after obtaining a positive culture (indirect method) 
(10). The pooled sensitivity and speciﬁ  city of the NRA (on 
culture isolates and sputum) have been reported to be 97% 
and 100% for rifampin and 96% and 99% for isoniazid 
(11). The pooled sensitivity and speciﬁ  city of direct NRA 
have been reported to be 99% and 100% for rifampin and 
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94% and 100% for isoniazid (12). A recent comparison of 
4 rapid DST methods with conventional DST in the context 
of a clinical trial suggested they may be cost-effective when 
compared with other health interventions (13). On the 
basis in part of these data, the World Health Organization 
(WHO) recently endorsed the use of NRA for screening 
patients at risk of MDR TB (14).
Despite the development of promising commercial 
and noncommercial rapid methods for MDR TB diagnosis, 
how to implement those methods under program 
conditions remains largely unaddressed. DST performance 
in validation studies differs greatly from performance 
integrated within a TB control program. Furthermore, the 
performance of any method under program conditions 
depends not only on assay characteristics, but also on the 
assets of the laboratory network and National Tuberculosis 
Control Program (NTP) guidelines which deﬁ  ne criteria for 
performing DST.
To address this gap, we evaluated the effects of a 
programmatic strategy for rapid screening for MDR TB 
among risk groups speciﬁ  ed by the Peruvian NTP in April 
2006 (15). At that same time, decentralized, district-level 
MDR TB screening was pilot tested in 2 district laboratories 
in Lima, Peru. In collaboration with the Peruvian NTP and 
the Peruvian National Reference Laboratory (NRL), we 
evaluated the effectiveness of these combined strategies 
for detecting MDR TB. We report the proportion of drug 
resistance among risk groups based on screening high-
risk patients as deﬁ  ned by explicit criteria, including rapid 
methods of DST in one of the ﬁ  rst countries to implement 
this strategy.
Materials and Methods
Study Setting and Program Description
The prevalence of TB in Peru was 38,000 cases, and the 
incidence of TB in Peru was 126 cases/100,000 population 
per year, by 2007 estimates (16). The most recent national 
surveillance data indicate 5.3% of new TB cases and 24% 
of previously treated TB cases are MDR TB (16). In 1996, 
a collaborative effort to provide individualized treatment 
by using second-line drugs for MDR TB in northern Lima 
was established by Partners In Health, Socios En Salud, 
Harvard University, the Massachusetts State Laboratory 
Institute, the Peruvian NTP, and the Peruvian INS (4). In 
October 1997, the Peruvian NTP began a standardized 
treatment regimen including directly observed therapy 
with second-line drugs for patients in whom ﬁ  rst-line 
drugs failed (17). Only 48% of these patients were treated 
successfully. During 2005 and 2006, the Peruvian INS 
and NTP transferred the capacity for DST to ﬁ  rst-line TB 
drugs from the central level at the NRL to 2 district-level 
reference laboratories in Lima as a prelude to decentralizing 
these services to all major provinces (4). Simultaneously, 
the NTP issued national guidelines codifying criteria for 
MDR TB screening on the basis of known and suspected 
risk factors for MDR TB. In addition, these guidelines 
recommended the use of a more aggressive empiric MDR 
TB treatment regimen, including 5 second-line drugs for 
those persons with suspected MDR TB pending DST 
results. These programmatic and laboratory efforts resulted 
in an integrated strategy to diagnose and treat MDR TB 
cases in a timely and aggressive manner. During this 
period, we evaluated the effectiveness of selection criteria 
for DST in the ﬁ  rst 2 laboratories (for health districts Lima 
Ciudad and Lima Este) where the NRA was implemented.
For persons in whom DST to ﬁ  rst-line drugs conﬁ  rmed 
drug resistance to isoniazid or rifampin, or both, the same 
isolate would be sent to the NRL for testing to a full panel of 
5 ﬁ  rst-line drugs and 5 second-line drugs. DST results were 
conveyed to health center providers by paper or electronic 
communication, and patients were evaluated with DST 
results to determine whether further regimen modiﬁ  cation 
was needed (18). Details of treatment regimens have been 
described elsewhere (19). All patients diagnosed with TB 
were provided directly observed therapy free of charge 
through the NTP.
Study Patients and Enrollment Period
The patients enrolled in this cohort had suspected TB 
with respiratory symptoms living in 2 districts of Lima, 
Peru, Lima Ciudad or Lima Este, who met Peruvian NTP 
guidelines for DST referral as elaborated in Table 1. There 
were no exclusion criteria.
Enrollment Methods
Patients were identiﬁ  ed by health care workers at their 
local health care establishments, and their sputum samples 
were sent to the reference laboratory for DST. Because 
all sputum samples for DST were sent to the district 
laboratories, subjects eligible for enrollment were identiﬁ  ed 
by this referral. Study personnel visited each district 
laboratory on a regular basis to review sample referrals and 
conﬁ  rm that all eligible subjects had been identiﬁ  ed. Large, 
busy health centers were visited weekly and smaller, rural 
health centers were visited at least monthly for review of 
patient medical records. This method was used to conﬁ  rm 
that all patients were included who were eligible without 
duplications. In Lima Ciudad, patients were enrolled from 
January 2005 through March 2008. In Lima Este, patients 
were enrolled from May 2005 through May 2008. 
Drug Susceptibility Methods
The scale-up of MDR TB laboratory services in Peru, 
including expansion of the BACTEC-460 system (Becton, 
Dickinson and Company, Sparks, MD, USA) and NRA 
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(Griess) method for rapid ﬁ   rst-line DST are described 
elsewhere (4,5,20). The Peruvian NRL performed 
BACTEC-460 culture and DST on paucibacillary and 
smear-negative samples, prioritizing pediatric cases, HIV-
positive persons, and health care workers. The scale-up of 
second-line conventional DST at the NRL by the indirect 
agar plate proportion method has also been described 
elsewhere (4). The district reference laboratories cultured 
sputum specimens processed with 4% NaOH on Ogawa 
medium without centrifugation. During 2005, BioSafety 
Level 3 working conditions were established in 2 district 
reference laboratories, and these laboratories implemented 
DST on LJ medium for ﬁ  rst-line drugs by using the indirect 
proportion method. Each procedure was validated by each 
laboratory through comparison with the Peruvian NRL and 
the Massachusetts State Laboratory Institute. Subsequently, 
the NRA was implemented in Lima Ciudad in December 
2005 and in Lima Este in March 2007. The study spanned 
pre- and postintervention periods: January 2005 through 
November 2008 for Lima Ciudad and May 2005 through 
November 2008 for Lima Este. The NRA was used for rapid 
screening of smear-positive specimens from patients with 
the risk factors outlined in Table 1. Sputum specimens were 
processed with 2% NaOH/N-acetyl-L-cysteine, centrifuged 
at 3,000 × g, cultured on LJ medium, and simultaneously 
inoculated on modiﬁ  ed LJ medium for the NRA to detect 
isoniazid and rifampin resistance.
Data Collection
A team of trained data recorders prospectively collected 
data using standardized forms. Sources of data included 
patient charts and laboratory registries and databases. HIV 
status was routinely recorded for TB patients. Available 
chest radiographs were reviewed by TB physicians who 
used standardized criteria to identify the type and location 
of radiographic abnormalities. Chest radiograph data were 
included if the radiograph was performed <1 year before 
the enrollment date or <1 month after the enrollment date. 
At baseline, clinical and sociodemographic data were 
recorded in addition to the risk factors outlined in Table 1. 
Data were entered into an Epi Info version 3.4.3 database 
(Centers for Disease Control and Prevention [CDC], 
Atlanta, GA, USA).
In addition to the data prospectively collected in this 
study, we used national and regional data from Peruvian 
NTP surveillance on drug resistance that were collected as 
part of the WHO Fourth Global Report on Anti-Tuberculosis 
Drug Resistance in the World (21). Surveillance and 
laboratory methods are described in more detail in the 
WHO report (21). For national data, we used all data in the 
NTP surveillance; for regional data, we included samples 
collected from health establishments served by the Lima 
Ciudad and Lima Este laboratories, which corresponded to 
the same catchment area as our study (Ministerio de Salud, 
unpub. data).
Patients were identiﬁ  ed as having MDR TB if they 
had a positive culture for M. tuberculosis and DST results 
showed resistance to at least isoniazid and rifampin. 
Extensively drug-resistant TB was deﬁ  ned as resistance to 
at least isoniazid, rifampin, any ﬂ  uoroquinolone, and >1 of 
3 injectable second-line drugs (amikacin, capreomycin, or 
kanamycin). Monoresistance was deﬁ  ned as drug-resistance 
to isoniazid or rifampin, but not both drugs. Patients were 
considered to have drug-susceptible TB if their isolate 
was susceptible to both isoniazid and rifampin. Baseline 
refers to DST data at the time of referral, i.e., testing 
performed on sputum samples collected within 30 days of 
study enrollment. If baseline drug resistance data were not 
available for both isoniazid and rifampin (e.g., because of a 
culture-negative sample or because of contamination), the 
patient was considered to have no DST result.
Statistical Analysis
All analyses were performed by using STATA/IC 
version 10.1 (StataCorp LP, College Station, TX, USA). 
The χ2 test or Fisher exact test was used to calculate p 
values, when appropriate. Point and interval estimation 
for the odds ratio were performed by using the Woolf 
procedure or the exact method, when appropriate. The 
Breslow-Day test for homogeneity was used to explore for 
effect modiﬁ  cation. All statistical tests were 2-sided, and 
signiﬁ  cance was set at α = 0.05.
Ethical Approval
The prospective observational cohort study providing 
data for this analysis was approved by institutional review 
boards at Brigham and Women’s Hospital and the Peruvian 
INS. An institutional review board amendment describing 
the aims of this analysis was approved by the Peruvian INS 
on October 15, 2008, and by the Partners Human Research 
Committee for Brigham and Women’s Hospital on 
September 23, 2008. This activity was approved by CDC 
as program evaluation and not as human subject research.
Results
A total of 1,846 patients were enrolled during the study 
period. Among these, 605 (32.8%) did not have baseline 
DST results, either due to a nonviable sample (99.2%) or 
incomplete resistance data for both isoniazid and rifampin 
(0.8%). The remaining 1,241 (67.2%) patients constitute 
the cohort for analysis presented here.
Of these 1,241, 419 (33.8%) had baseline MDR TB, 
among whom 195 (46.5%) had never been treated for TB 
and 224 (53.5%) had a history of previous TB treatment. 
Eight patients had extensively drug-resistant TB; 1 was 
a medical student, 1 had received prior self-administered 
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treatment, 2 had household contacts (1 was a pediatric 
patient and the other was an adult), and 4 were identiﬁ  ed 
as suspected category I failures, i.e., failure of ﬁ  rst-line 
treatment for new patients. Of these 8 case-patients, only 
1 (who had received self-administered treatment) had 
completed previous treatment.
Descriptive characteristics of the cohort are shown 
in Table 2. Compared with patients with drug-susceptible 
TB, those with MDR TB were younger, more likely to be 
single, more educated, and less likely to have ever smoked. 
Clinically, they were less likely to have been tested by 
using the BACTEC-460 system and more likely to have 
hemoptysis. MDR TB patients and patients with drug-
susceptible TB did not signiﬁ   cantly differ with respect 
to their year of enrollment, gender, and history of TB 
treatment. Compared with patients with drug-susceptible   
TB, patients with monoresistant TB were younger and 
more likely to be single.
The most frequent risk factors prompting referral for 
DST among patients with new smear-positive TB were 
being adults with a household contact with known or 
suspected MDR TB (32.1%), diabetes mellitus (20.0%), 
and suspected category I failures (19.5%). Among 
previously treated patients with smear-positive TB, those 
with multiple (>2) treatments (43.2%), adult household 
contact (18.6%), default of category I treatment (16.8%), 
and previously self-administered treatment (14.9%) were 
most frequently referred for DST. Among all patients with 
smear-positive TB, a single risk factor was identiﬁ  ed in 485 
(43.54%) patients, whereas 382 (34.29%), 205 (18.40%), 
38 (3.41%), and 4 (0.36%) had 2, 3, 4, and 5 risk factors, 
respectively (data not shown).
The prevalence of MDR TB in Peru in 2007 among 
all TB patients, previously treated TB patients, and new 
TB patients is shown in Table 3 (21). In this national 
surveillance report, 8.3% of all TB patients, 5.2% of new 
TB patients, and 24.2% of previously treated TB patients 
in Peru were estimated to have MDR TB (21). Limiting 
surveillance data to the 2 districts where our cohort was 
enrolled, 12.4% of all TB patients, 9.9% of new TB 
patients, and 24.0% of previously treated TB patients had 
MDR TB (Ministerio de Salud, unpub. data). In our cohort 
of 1,241 subjects, 33.8% of all patients, 31.6% of new TB 
patients, and 35.8% of previously treated TB patients had 
MDR TB. Because national surveillance was conducted on 
smear-positive samples only, we compared the proportion 
of MDR TB among patients with smear-positive results 
in our cohort to prevalence of MDR TB from regional 
surveillance estimates. As shown in Tables 4 and 5, our 
cohort showed higher risk for MDR TB among new TB 
patients and previously treated TB patients.
When stratifying our cohort by risk group, we found 
that diabetes mellitus (16.8%), adult (33.5%) or child 
(53.9%) patients with household contacts with known 
or suspected MDR TB, and suspected category I failure, 
i.e., positive smear or culture during the second or third 
month of category I therapy (66.7%), were associated 
with signiﬁ  cantly higher relative risks of MDR TB among 
patients with new smear-positive TB, when compared to 
regional surveillance prevalence estimates. Among the 18 
patients with diabetes and new smear-positive MDR TB, 
10 (55.6%) had 2 risk factors for MDR TB at the time of 
enrollment. Of these, 5 (27.8%) had suspected category I 
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Table 1. Criteria for drug-susceptibility testing referral per 
Peruvian National Tuberculosis Control Program guidelines* 
A. Newly diagnosed smear- or culture-positive patients at risk for 
MDR TB. Persons were eligible for enrollment if they were  
1) diagnosed with smear-positive pulmonary TB, 2) had no 
history of TB, and 3) had >1 of the following risk factors: 
  1. Household contact of patient with documented MDR TB 
  2. Household contact of patient in treatment with second-line 
drugs 
  3. Household contact of patient who showed failure of TB 
therapy 
  4. Household contact of patient who died of TB within the past 
2 years 
  5. HIV-positive by ELISA and Western blot confirmation 
  6. Diabetes mellitus 
  7. Health care worker, regardless of health care field, in the 
past 2 years 
  8. Student of health sciences in the past 2 years 
  9. Employee of the penitentiary system 
  10. Chronic treatment with corticosteroids 
  11. Other condition of immunosuppression 
  12. Adverse reaction to TB medications requiring a change in 
regimen 
  13. Hospitalization for any indication in the past 2 years lasting 
>15 days 
B. Patients in whom first-line or second-line therapy may be 
failing. Persons were eligible for enrollment if they were 1) 
currently receiving first-line or second-line treatment, and 2) had 
a sputum sample collected after >2 months of treatment that was 
smear positive (i.e., monthly sputum collected between months 2 
and 6) 
C. Patients who had received >1 previous treatment and who did 
not have documented MDR TB. This included persons who: 
  1. Abandoned any previous regimen and now presented for 
retreatment 
  2. Relapsed after completion of any previous regimen within 6 
months
  3. Unsuccessful treatment with any previous regimen 
  4. Received multiple courses of TB treatment 
  5. Had a history of private or auto-administered treatment 
D. Newly diagnosed smear-negative patients at risk for smear-
negative MDR TB. Persons were eligible for enrollment if they 
were 1) suspected to have active pulmonary TB, 2) were smear 
negative, 3) had no history of TB therapy, and 4) had >1 of the 
following risk factors: 
  1. Pediatric household contact of patient with documented 
MDR TB 
  2. Pediatric household contact of patient who died of 
tuberculosis within the past 2 years 
  3. HIV positive by ELISA and Western blot confirmation 
*MDR, multidrug resistant; TB, tuberculosis. RESEARCH
failure, 4 (22.2%) were adults with a household contact, 
and 1 (5.6%) had conﬁ  rmed category I failure. Breslow-
Day tests for homogeneity indicated that the effect of adult 
household contact on the odds of MDR TB is modiﬁ  ed 
by diabetes (p<0.0001), and that the effect of suspected 
category I failure on the odds of MDR TB is modiﬁ  ed 
by diabetes (p = 0.0113). One patient with new smear-
positive TB was suspected of failing category II treatment 
(i.e., positive smear or culture during the second or third 
month of category II therapy); this same patient met the 
risk group criteria for adult household contact and private 
or self-administered treatment. Among previously treated 
patients with smear-positive TB, the following factors 
were signiﬁ  cantly associated with a higher relative risk for 
MDR TB, compared with regional surveillance prevalence 
estimates: adult household contact (51.4%), failure of 
category I treatment (73.3%), early relapse after category 
I treatment (40.0%), suspected (84.6%) or conﬁ  rmed 
(61.1%) failure of category II treatment, and history of >2 
previous TB treatments (38.3%).
Discussion
We describe the proportion of drug resistance among 
TB patients as detected by using the screening strategy 
for MDR TB instituted in Lima, Peru, starting in 2005. 
When these data were compared with nearly concurrent 
population-based surveillance data, the proportion of MDR 
TB among new and previously treated TB cases was found 
to be signiﬁ  cantly higher, indicating that screening high-
risk patients may be an effective strategy. The proportion of 
MDR TB detected among patients with new smear-positive 
TB is comparable to that among previously treated patients 
with smear-positive TB in the cohort (p = 0.458). In the 
Peruvian NTP surveillance regional data corresponding to 
the study area, the prevalence of MDR TB among patients 
with new smear-positive TB was signiﬁ  cantly lower than the 
prevalence among previously treated patients with smear-
positive TB (p<0.001). This ﬁ  nding shows that the strategy 
implemented in Lima was especially effective in detecting 
MDR TB among patients with new smear-positive TB.
The risk groups with the highest rates of MDR TB 
were those with diabetes mellitus, adults or children with 
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Table 2. Demographic and clinical characteristics of patients with tuberculosis, by drug-resistance status, Lima, Peru, 2005–2008* 
Variable
Susceptible to INH 
and RIF, n = 661 
Monoresistant to INH 
or RIF, n = 161  MDR TB, n = 419  Total, N = 1,241
DST method 
  Griess  318 (48.1)  87 (54.0)  208 (49.6)  613 (49.4) 
  Conventional  270 (40.9)  56 (34.8)  185 (44.2)  511 (41.2) 
  BACTEC  63 (9.5)  17 (10.6)  23 (5.5)† 103 (8.3) 
  Griess/BACTEC  10 (1.5)  1 (0.6)  3 (0.7)  14 (1.1) 
Year of enrollment 
2005  175 (26.5)  44 (27.3)  130 (31.0)  349 (28.1) 
2006  233 (35.3)  47 (29.2)  127 (30.3)  407 (32.8) 
2007  178 (26.9)  48 (29.8)  106 (25.3)  332 (26.8) 
2008  75 (11.4)  22 (13.7)  56 (13.4)  153 (12.3) 
Age, y, mean r SD  35.6 ± 15.2  32.8 ± 15.1† 29.7 ± 13.1‡ 33.2 ± 14.8 
Female sex  236 (35.7)  54 (33.5)  144 (34.4)  434 (35.0) 
Married or lived together  272 (41.2) 48 (29.8)§ 136 (32.5)§ 456 (36.7) 
Unemployed, n = 1,239  257 (38.9)  62 (38.8)  155 (37.0)  474 (38.3) 
Did not begin secondary level education, n = 1,235  150 (22.9)  31 (19.3)  67 (16.0)§ 248 (20.1) 
Tobacco use (ever), n = 1,240  191 (28.9)  48 (29.8)  97 (23.2)† 336 (27.1) 
Alcohol use or abuse (ever), n = 1,240  257 (38.9)  61 (37.9)  148 (35.3)  466 (37.6) 
Illicit drug use (ever)  131 (19.8)  38 (23.6)  77 (18.4)  246 (19.8) 
Weight loss, n = 1,237  543 (82.5)  126 (78.8)  330 (78.8)  999 (80.8) 
Dyspnea, n = 1,238  118 (17.9)  21 (13.1)  81 (19.3)  220 (17.8) 
Hemoptysis, n = 1,239  28 (4.3)  9 (5.6)  38 (9.1)§ 75 (6.1) 
Cavitary lesion on chest radiography, n = 1,207  199 (16.5)  43 (3.6)  144 (11.9)  386 (32.0) 
Low BMI, n = 1,233  203 (30.8)  55 (34.8)  133 (32.1)  391 (31.7) 
Previous TB treatment  328 (49.6)  77 (47.8)  224 (53.5)  629 (50.7) 
Type of TB 
  Pulmonary only  650 (98.3)  155 (96.3)  414 (98.8)  1219 (98.2) 
  Extrapulmonary  11 (1.7)  6 (3.7)  5 (1.2)  22 (1.8) 
*Values are no. (%) except as indicated. Boldface indicates significant difference in statistical comparison of baseline characteristics in the corresponding 
drug-resistance group to drug-susceptible cases. INH, isoniazid; RIF, rifampin; MDR TB, multidrug-resistant tuberculosis; DST, drug-susceptibility testing; 
BMI, body mass index. 
†p<0.05. 
‡p<0.001. 
§p<0.01. Targeted Drug-Resistance Testing Strategy for MDR TB
household contacts with known or suspected TB, suspected 
failure of category I or II treatment (i.e., positive smear or 
culture during the second or third month of therapy), failure 
or early relapse to category I treatment, failure of category 
II treatment, and multiple (>2) previous TB treatments. 
Ample literature supports these ﬁ  ndings in a variety of 
settings (22–25). Screening for drug resistance among 
these groups is easily implemented and should be strongly 
considered by national TB programs.
In addition to identifying risk groups with high 
prevalence of MDR TB, other considerations are pertinent 
to the design of an optimal programmatic strategy. For 
example, risk groups with a relatively low prevalence of 
MDR TB may still merit DST if delays in initiation of MDR 
TB treatment would have severe consequences (e.g., children 
or HIV-positive patients) or if the absolute number of MDR 
TB cases within that risk group is substantial (e.g., patients 
with diabetes). The relative complexity of implementing 
certain testing strategies is also a consideration. Compared 
with alternative testing strategies such as universal testing or 
testing by geographic region, a strategy that focuses on high-
risk patients requires training health care workers to screen 
each TB patient for numerous risk factors. Therefore, case 
ﬁ  nding may be variable under routine program conditions.
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Table 3. Prevalence estimates of TB drug resistance from national and regional surveillance data, and proportion of drug resistance in 




No. (%) susceptible 
to INH and RIF 
No. (%) monoresistant 
to INH or RIF 
No. (%)  
MDR TB 
Peruvian NTP drug-resistance surveillance, national data (21)
  All TB patients  2,167  1,829 (84.4)  158 (7.3)  180 (8.3) 
  New TB patients  1,816  1,597 (87.9)  124 (6.8)  95 (5.2) 
  Previously treated TB patients  351 232 (66.1)  34 (9.7)  85 (24.2) 
Peruvian NTP drug-resistance surveillance, regional data corresponding to study area† 
  All TB patients  580 467 (80.5)  41 (7.1)  72 (12.4) 
  New TB patients  476 396 (83.2)  33 (6.9)  47 (9.9) 
  Previously treated TB patients  104 71 (68.3)  8 (7.7)  25 (24.0) 
Study cohort 
  All TB patients  1,241  661 (53.3)  161 (13.0)  419 (33.8) 
  New TB patients  612 333 (54.4)  84 (13.7)  195 (31.9) 
  Previously treated TB patients  629 328 (52.2)  77 (12.2)  224 (35.6) 
Study cohort, smear-positive samples only 
  All TB patients  1,114  581 (52.2)  143 (12.8)  390 (35.0) 
  New TB patients  531 278 (52.4)  73 (13.8)  180 (33.9) 
  Previously treated TB patients  583 303 (52.0)  70 (12.0)  210 (36.0) 
*TB, tuberculosis; INH, isoniazid; RIF, rifampin; MDR, multidrug resistant; NTP, National Tuberculosis Control Program. 
†Ministerio de Salud, Peru, unpub. data. 
Table 4. MDR TB among new smear-positive TB patients compared with regional surveillance prevalence estimates, by NTP risk 
group, Lima, Peru, 2005–2008* 
Risk factor  Total no. patients 
No. (%)  
MDR TB  Odds ratio (95% CI) 
New smear-positive TB patients in NTP regional surveillance data  476 47 (9.9) 
New smear-positive TB patients in study cohort  531 180 (33.9)  4.68 (3.30–6.65) 
HIV positive  46 8 (17.4)  1.92 (0.85– 4.36) 
Diabetes mellitus  107 18 (16.8)  1.85 (1.02–3.33) 
Chronic corticosteroid therapy  4 0 NA
Other immunosuppression  5 0 NA
Adverse reaction  4 1 (25.0)  3.04 (0.06–38.63) 
Previous hospitalization within the past 2 y with duration >15 d  5 2 (40.0)  6.09 (0.49–54.15) 
Health care worker during the past 2 y  24 4 (16.7)  1.83 (0.60–5.57) 
Health sciences student during the past 2 y  29 5 (17.2)  1.90 (0.69–5.22) 
Prisoner during the past 2 y  27 4 (14.8)  1.59 (0.53–4.79) 
Adult patient with household contact risk factor(s)†  170 57 (33.5)  4.60 (2.97–7.14) 
Pediatric patient with household contact risk factor(s)†  13 7 (53.9)  10.65 (2.90–39.71) 
Private or self-administered treatment  2 2 (100.0)  NA
Sputum positive during second or third month of category I treatment  105 70 (66.7)  18.26 (11.01–30.26) 
Sputum positive during second or third month of category II treatment  1 1 (100.0)  NA
*MDR, multidrug resistant; TB, tuberculosis; NTP, National Tuberculosis Control Program; CI, confidence interval; NA, not applicable.  
†Household contact risk factors are defined as household contact with a patient with known MDR TB, with a patient who showed TB treatment failure in 
the past 2 y, or with a patient being treated with second-line TB drugs.  RESEARCH
The ﬁ  ndings of this evaluation are subject to several 
limitations. Although our study personnel would visit local 
health establishments in a purely observational capacity, the 
frequent visits by data collectors in the health centers could 
have sensitized health care workers to follow screening 
and referral protocols more closely than they would have 
otherwise. In addition, given the use of phenotypic methods, 
the drug-resistance status of particular isolates could be 
determined only for culture-positive samples. Although 
the yield of positive cultures was high for all methods used 
(67.4% for indirect conventional DST, 78.5% for direct 
NRA, and 35.3% for largely paucibacillary or smear-
negative samples submitted for BACTEC; data not shown), 
the contribution to relative risk of MDR TB among those 
without DST results could not be determined. These results 
call attention to one of the shortcomings of all phenotypic 
methods, i.e., a substantial fraction of patients never have 
positive cultures or DST results to conﬁ  rm the diagnosis 
or guide therapy, despite being at high risk for having 
MDR TB. Nonetheless, the yield of positive cultures in 
our sample is similar to that obtained by programs that 
have used the same sputum-processing methods (N-acetyl-
L-cysteine and centrifugation, with cultivation on LJ 
medium). Finally, this evaluation was observational in 
nature and lacks a concurrent comparison group, such as 
one that had undergone an alternative screening strategy. 
On the other hand, this study has key strengths. The 
programmatic nature of this intervention, an active ﬁ  eld 
presence to capture accurate and complete data on a large 
cohort, and the fortuitous concurrent surveillance study 
have allowed us to assess the effects of these programmatic 
efforts to identify patients with MDR TB.
To date, little research has been conducted on the 
comparative effectiveness of varied approaches to MDR 
TB screening and treatment referral. To our knowledge, 
the only study to show clinical results for performing rapid 
DST is a retrospective study carried out in California, 
which showed that using a molecular beacon assay led to 
earlier diagnosis and treatment initiation for MDR TB (26). 
An important aspect of program evaluation is feedback 
of  ﬁ   ndings to further improve treatment programs. In 
Peru, the results of this evaluation have been conveyed to 
the NTP and NRL. The aim of this communication is to 
describe an intensive evaluation of one of Peru’s public 
health strategies for improving MDR TB control. In 
other low- to middle-income countries, similar program 
evaluations should be implemented to clarify national and 
regional MDR TB epidemiology, identify key risk groups 
for MDR TB, and inform national strategies to diagnose 
and treat MDR TB. Ultimately, the effects of these changes 
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Table 5. MDR TB among previously treated smear-positive TB patients compared with regional surveillance prevalence estimates, by




No. (%)  
MDR TB  Odds ratio (95% CI) 
Previously treated smear-positive TB patients in NTP regional surveillance data  104 25 (24.0) 
Previously treated smear-positive TB patients in study cohort  583 210 (36.0)  1.78 (1.10–2.88) 
HIV positive  36 12 (33.3)  1.58 (0.69–3.61) 
Diabetes mellitus 30 10 (33.3)  1.58 (0.65–3.82) 
Adverse reaction  13 1 (7.7)  0.26 (0.01–1.97) 
Previous hospitalization within the past 2 y with duration >15 d  4 1 (25.0)  1.05 (0.02–13.80) 
Health care worker during the past 2 y  4 1 (25.0)  1.05 (0.02–13.80) 
Health sciences student during the past 2 y  4 3 (75.0)  9.48 (0.71–503.7) 
Prisoner during the past 2 y  24 4 (16.7)  0.63 (0.20–2.02) 
Adult case with household contact risk factor(s)† 109 56 (51.4)  3.34 (1.86–6.00) 
Pediatric case with household contact risk factor(s)† 7 3 (42.9)  2.37 (0.32–14.92) 
Private or self-administered treatment  87 28 (32.2)  1.50 (0.79–2.83) 
Sputum positive during second or third month of category I treatment  5 3 (60.0)  4.74 (0.50–58.69) 
Sputum positive during second or third month of category II treatment  13 11 (84.6)  17.38 (3.36–166.8) 
Failure of category I treatment‡  30 22 (73.3)  8.69 (3.44–21.93) 
Relapsed within 6 mo after category I treatment§  65 26 (40.0)  2.11 (1.08–4.12) 
Defaulted while receiving category I treatment¶  98 15 (15.3)  0.57 (0.28–1.16) 
Failure of category II treatment‡  18 11 (61.1)  4.97 (1.74–14.18) 
Relapsed within 6 mo after category II treatment§  8 5 (62.5)  5.27 (0.93–35.66) 
Defaulted while receiving category II treatment¶  63 16 (25.4)  1.08 (0.52–2.22) 
Chronic treatment (>2 prior treatments)#   253 97 (38.3)  1.96 (1.17–3.29) 
*MDR, multidrug resistant; TB, tuberculosis; CI, confidence interval; NTP, National Tuberculosis Control Program. 
†Household contact risk factors are defined as household contact with a patient with known MDR TB, with a patient who showed TB treatment failure in 
the past 2 y, or with a patient being treated with second-line TB drugs. 
‡Defined as positive smear and/or culture after >4 mo of treatment, or positive smear and/or culture upon finishing treatment. 
§Defined as recurrence of disease <6 mo after being classified as cured by NTP norms. 
¶Defined as not receiving treatment >1 mo upon enrollment into the study. 
#Defined as a history of >2 previous TB treatments. Targeted Drug-Resistance Testing Strategy for MDR TB
on turn-around time, time to culture conversion, cure rates, 
and costs will determine the comparative success of these 
strategies. 
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